New York State Teachers Retirement System Decreases Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

New York State Teachers Retirement System cut its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 0.9% in the third quarter, HoldingsChannel reports. The firm owned 43,318 shares of the specialty pharmaceutical company’s stock after selling 391 shares during the quarter. New York State Teachers Retirement System’s holdings in Jazz Pharmaceuticals were worth $4,826,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Versant Capital Management Inc lifted its position in Jazz Pharmaceuticals by 13,450.0% during the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock valued at $29,000 after purchasing an additional 269 shares during the last quarter. Itau Unibanco Holding S.A. purchased a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter valued at about $29,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Jazz Pharmaceuticals by 55.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after acquiring an additional 97 shares during the last quarter. GAMMA Investing LLC grew its position in Jazz Pharmaceuticals by 65.5% in the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 116 shares in the last quarter. Finally, Gladius Capital Management LP bought a new stake in Jazz Pharmaceuticals during the second quarter worth approximately $33,000. Institutional investors own 89.14% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Robert W. Baird lowered their price objective on Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating for the company in a research note on Thursday, August 1st. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, August 1st. StockNews.com upgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Royal Bank of Canada raised their target price on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an “outperform” rating in a report on Wednesday, October 23rd. Finally, Needham & Company LLC reissued a “buy” rating and issued a $205.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday, September 10th. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $173.43.

Jazz Pharmaceuticals Trading Up 1.8 %

JAZZ opened at $111.43 on Wednesday. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. The stock’s fifty day moving average is $110.51 and its two-hundred day moving average is $109.60. The company has a market capitalization of $6.88 billion, a P/E ratio of 19.15, a PEG ratio of 1.38 and a beta of 0.57. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $134.48.

Insider Activity

In related news, SVP Mary Elizabeth Henderson sold 1,410 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the sale, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at $1,573,707.30. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction on Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the sale, the chief executive officer now owns 428,976 shares of the company’s stock, valued at approximately $47,547,699.84. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the business’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the transaction, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.